研究目的
To investigate the associations of metabolite levels derived from magnetic resonance spectroscopic imaging (MRSI) and 18F-?uciclovine positron emission tomography (PET) with prostate tissue characteristics.
研究成果
Simultaneous acquisition of 18F-?uciclovine PET and MRSI is feasible in patients with prostate cancer, showing a significant correlation between SUVmean and SUVmax with the CSC/C ratio. A combination of these imaging modalities can improve the diagnostic accuracy of assessing prostate cancer lesions.
研究不足
The study did not examine the reproducibility of the imaging techniques, had a small patient cohort of only 19 high-risk prostate cancer patients, and included only 23% of the available spectroscopic voxels based on quality criteria.
1：Experimental Design and Method Selection:
The study involved simultaneous PET/MRI acquisition in high-risk prostate cancer patients to evaluate the diagnostic performance of MRSI and PET.
2：Sample Selection and Data Sources:
19 high-risk prostate cancer patients were selected for the study, with whole-mount histopathology used as the gold standard.
3：List of Experimental Equipment and Materials:
An integrated
4：0T PET/MRI system (Magnetom Biograph mMR, Siemens Healthineers) was used for imaging. Experimental Procedures and Operational Workflow:
The protocol included a full clinical mpMRI examination combined with simultaneous PET imaging, using 18F-?uciclovine as the PET tracer.
5：Data Analysis Methods:
Spectral data were analyzed using jMRUI v5.2, and statistical analyses were performed using SPSS and MedCalc Statistical Software.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
